Atossa遗传学 ATOS 深 沪
已收盘 12-19 16:00:00 美东时间
0.7322
+0.028
+3.98%
华盛通- 最 高0.99
- 今 开0.71
- 成交量 93.04万股
- 最 低 0.6848
- 昨 收 0.7042
- 总市值 9298.94万
- 52周最高 1.29
- 市盈率 静 --
- 换手率 0.73%
- 52周最低 0.5526
- 委 比 75.40%
- 总股本 1.27亿
- 历史最高 2232.00
- 量 比 0.82
- 振 幅 43.34%
- 历史最低 0.50
- 每 手 1
- 风险率 0.10%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Atossa Therapeutics Presents Four Clinical Trial Updates On (Z)-Endoxifen At SABCS
Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reductionSEATTLE, Dec. 15, 2025 /PRNewswire/ -- Atossa Therapeutics, Inc. (NASDAQ:ATOS) ("Atossa" or the
12-15 21:03
Why Are Shares Of Atossa Therapeutics Up Today?
Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock is trading higher on Thursday. Here's what investors need to know.
12-12 01:26
Atossa Therapeutics Secures U.S. Patent for Methods of Making And Using Endoxifen
New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditionsSEATTLE, Dec. 9, 2025 /PRNewswire/ -- Atossa
12-09 21:06
Atossa Highlights (Z)-Endoxifen's Multi-Pathway Potential In Duchenne Muscular Dystrophy And Carrier-Associated Pathologies
Published article outlines rationale for multi-pathway efficacy for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD); November scientific presentation to spotlight potential in Duchenne carrier–associated
11-17 22:11
Atossa Therapeutics Q3 EPS $(0.07), Inline
Atossa Therapeutics (NASDAQ:ATOS) reported quarterly losses of $(0.07) per share which met the analyst consensus estimate. This is a 16.67 percent decrease over losses of $(0.06) per share from the same period last year.
11-12 21:18
2025-2031年电液伺服系统行业细分市场前瞻及投资战略咨询报告
（转自：普华有策） 展望“十五五”电液伺服系统行业发展有利因素分析 1、电液伺服系统行业定义及分类情况 伺服系统是交流伺服系统和电液伺服系统的统称，其功能是通过...
06-25 14:15
展望“十五五”电液伺服系统行业发展有利因素分析
（转自：普华有策） 展望“十五五”电液伺服系统行业发展有利因素分析 1、电液伺服系统行业定义及分类情况 伺服系统是交流伺服系统和电液伺服系统的统称，其功能是通...
06-25 13:41
Domino's Pizza To $510? Here Are 10 Top Analyst Forecasts For Wednesday
Top Wall Street analysts changed their outlook on these top names. For a comple...
2024-09-11 21:08
Ascendiant Capital Maintains Buy on Atossa Therapeutics, Raises Price Target to $6.5
Ascendiant Capital analyst Edward Woo maintains Atossa Therapeutics (NASDAQ:ATOS) with a Buy and raises the price target from $6.25 to $6.5.
2024-09-11 17:46
Atossa Therapeutics Secures New US Patent for Breast Cancer Treatment Endoxifen
09:12 AM EDT, 08/28/2024 (MT Newswires) -- Atossa Therapeutics (ATOS) said Wednesday that the US Patent and Trademark Office has granted it a new patent covering compositions of endoxifen and an enteric-coating material in which at least 90% of the endoxifen is (Z)-endoxifen. The breast cancer-focus...
2024-08-28 21:12
